EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

DrugDomain : The evolutionary context of drugs and small molecules bound to domains

Kirill E Medvedev iD, R Dustin Schaeffer iD, Nick V Grishin

Protein Science · 2024-08 · 33 (8)

DOI: 10.1002/pro.5116 ↗

At a glance

Journal article in Protein Science, published online on 2024-07-09. Written by Kirill E Medvedev and 2 co-authors. Institution: Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Proteins, Protein Domains. Cited 9 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Science Foundation, NIGMS NIH HHS, Welch Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Interactions between proteins and small organic compounds play a crucial role in regulating protein functions. These interactions can modulate various aspects of protein behavior, including enzymatic activity, signaling cascades, and structural stability. By binding to specific sites on proteins, small organic compounds can induce conformational changes, alter protein–protein interactions, or directly affect catalytic activity. Therefore, many drugs available on the market today are small molecules (72% of all approved drugs in the last 5 years). Proteins are composed of one or more domains: evolutionary units that convey function or fitness either singly or in concert with others. Understanding which domain(s) of the target protein binds to a drug can lead to additional opportunities for discovering novel targets. The evolutionary classification of protein domains (ECOD) classifies domains into an evolutionary hierarchy that focuses on distant homology. Previously, no structure‐based protein domain classification existed that included information about both the interaction between small molecules or drugs and the structural domains of a target protein. This data is especially important for multidomain proteins and large complexes. Here, we present the DrugDomain database that reports the interaction between ECOD of human target proteins and DrugBank molecules and drugs. The pilot version of DrugDomain describes the interaction of 5160 DrugBank molecules associated with 2573 human proteins. It describes domains for all experimentally determined structures of these proteins and incorporates AlphaFold models when such structures are unavailable. The DrugDomain database is available online: http://prodata.swmed.edu/DrugDomain/ .

Subjects

MeSH terms (MEDLINE)

ProteinsProtein DomainsPharmaceutical PreparationsDatabases, ProteinHumansSmall Molecule LibrariesEvolution, MolecularProtein Binding

Author keywords

domaindrugsprotein structuresmall moleculestarget

Substances

ProteinsPharmaceutical PreparationsSmall Molecule Libraries

Authors and institutions

  • Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID profiles: Kirill E Medvedev, R Dustin Schaeffer

Funding

  • National Science Foundation
  • NIGMS NIH HHS
  • Welch Foundation
  • National Institute of General Medical Sciences

Cite

APA

Medvedev, K. E., Schaeffer, R. D., & Grishin, N. V. (2024). DrugDomain : The evolutionary context of drugs and small molecules bound to domains. Protein Science, 33(8). https://doi.org/10.1002/pro.5116

Vancouver

Medvedev KE, Schaeffer RD, Grishin NV. DrugDomain : The evolutionary context of drugs and small molecules bound to domains. Protein Science. 2024;33(8). doi:10.1002/pro.5116

BibTeX
@article{Medvedev2024,
  author = {Medvedev, Kirill E and Schaeffer, R Dustin and Grishin, Nick V},
  title = {DrugDomain : The evolutionary context of drugs and small molecules bound to domains},
  journal = {Protein Science},
  year = {2024},
  volume = {33},
  number = {8},
  doi = {10.1002/pro.5116}
}
Start for free →